Schroder Investment Management Group’s Trinity Biotech TRIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
Sell
-99,320
Closed -$6.57M 1190
2016
Q3
$6.57M Hold
99,320
0.01% 692
2016
Q2
$5.63M Hold
99,320
0.01% 709
2016
Q1
$5.71M Hold
99,320
0.01% 674
2015
Q4
$5.84M Buy
99,320
+8,720
+10% +$515K 0.01% 716
2015
Q3
$5.18M Buy
90,600
+120
+0.1% +$9.65K 0.01% 739
2015
Q2
$8.15M Sell
90,480
-1,340
-1% -$116K 0.02% 677
2015
Q1
$8.64M Sell
91,820
-1,640
-2% -$152K 0.02% 676
2014
Q4
$8.18M Hold
93,460
0.02% 689
2014
Q3
$8.54M Buy
93,460
+2,100
+2% +$227K 0.01% 698
2014
Q2
$10.5M Buy
91,360
+46,460
+103% +$5.51M 0.01% 622
2014
Q1
$5.44M Buy
+44,900
New +$5.89M 0.01% 756

Other funds holding TRIB

Schroder Investment Management Group's TRIB Position: Q4 2016 in Review

Schroder Investment Management Group sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 99,320 shares — an estimated $6.57M sold.

Schroder Investment Management Group first reported a position in TRIB in Q1 2014 and held it in 11 quarters. The position peaked at $10.5M in Q2 2014. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

  • Schroder Investment Management Group reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
  • Schroder Investment Management Group sold 99,320 Trinity Biotech shares in Q4 2016, an estimated $6.57M.
  • Schroder Investment Management Group first reported a position in Trinity Biotech in Q1 2014 and held it in 11 quarters.
  • Schroder Investment Management Group's Trinity Biotech position peaked at $10.5M in Q2 2014.
  • 71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Schroder Investment Management Group's 13F filing for Q4 2016, filed 10 Feb 2017.